



Emerging Issue of Inflammatory Bowel Diseases

Guest Editor:

Dr. Agata Michalak

Department of Gastroenterology
with Endoscopy Unit, Medical
University of Lublin, 20-954
Lublin, Poland

Deadline for manuscript
submissions:

30 December 2024

Message from the Guest Editor

Dear Colleagues, Inflammatory bowel diseases (IBDs) are currently crucial pathologies. We still do not know their exact origin, and despite the ongoing era of biologics in their treatment, Crohn's disease and ulcerative colitis tend to be somehow unpredictable in their course. We gather continuously more information related to IBDs. To emphasize the current role of IBDs and to explore molecular pathways involved in their development, we highly encourage you to publish in the Special Issue of Biomedicines titled Emerging Issue of Inflammatory Bowel Diseases. The scope of the manuscripts should be related to the following topics: Original data on novel markers in the diagnosis IBDs and in the prediction of their flare up; Possible new indicators of the positive treatment response; New approaches in the management of IBDs, including combinations of biologics; Markers predicting the natural history of IBDs; Comorbidities observed in patients with IBDs and the general outcome in this population; The context of colorectal cancer in patients with IBDs; Future perspectives for IBDs, including medical and social aspects.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI